查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球下呼吸道疾病诊断和治疗市场
市场调查报告书
商品编码
1327652

2023-2030年全球下呼吸道疾病诊断和治疗市场

Global Lower Respiratory Tract Disease Diagnosis and Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

预计全球下呼吸道疾病诊断和治疗市场在预测期内（2023-2030年）将以7.4%的复合年增长率增长。下呼吸道疾病诊断和治疗市场的驱动因素包括下呼吸道疾病发病率上升、人口老龄化、意识和诊断的提高、政府倡议和医疗政策、环境变量（如空气污染、气候变化和过敏原） ，以及技术创新。由于全球多个国家的空气质量日益恶化，导致感冒、咳嗽和过敏的发病率增加。因此，有多项倡议旨在改善空气质量指数（AQI），同时提供高效的医疗设施来治疗此类感染。例如，2023 年 3 月，伦敦超低排放区（ULEZ）项目采用移动空气质量监测技术来跟踪空气质量，计划到 2050 年减少 100 万人住院治疗。被污染的空气。

细分市场前景

全球下呼吸道疾病诊断和治疗市场按病情、诊断、治疗和类别细分。根据情况，市场分为肺炎、支气管炎、肺结核和其他（流感）。根据诊断，市场细分为粘液样本、血液测试、胸部 X 光检查和脉搏血氧测定。根据治疗方法，市场细分为非甾体抗炎药、镇痛药和退烧药、支气管扩张吸入器和其他药物（抗生素）。此外，根据类别，市场分为非处方药和处方药。在这些疾病中，由于支气管炎病例患病率的上升以及治疗支气管炎的新的和更有效的药物的开发的增加，预计支气管炎细分市场将占据相当大的市场份额。

预计支气管扩张吸入器细分市场将占据相当大的市场份额

其中，支气管扩张吸入器细分市场预计将在全球下呼吸道疾病诊断和治疗市场中占据相当大的份额。细分市场的增长归因于联合疗法日益增长的影响力。结合两种或多种支气管扩张吸入剂药物的联合疗法变得越来越普遍，因为它们提供更好的治疗效果并且对患者来说更方便。例如，2020 年8 月，Teva Pharmaceutical Industries Ltd. 推出了ProAir (R) Digihaler (R)（硫酸沙丁胺醇117 mcg）吸入粉，这是第一个也是唯一一个被批准用于4 岁及以上患者的数字救援吸入器。该吸入器用于治疗和预防可逆性阻塞性气道疾病患者的支气管痉挛，以及避免运动诱发的支气管痉挛 (EIB)。

区域展望

全球下呼吸道疾病诊断和治疗市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、意大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于亚太地区人口不健康的生活方式，预计该地区将在全球市场中占据显着份额。扩大医疗基础设施和提高患者意识是推动区域市场增长的另一个因素。

北美全球下呼吸道疾病诊断和治疗市场预计将以显着的复合年增长率增长

在所有地区中，预计北美地区在预测期内将以显着的复合年增长率增长。不断增长的老年人口、免疫力低下的老年人和儿童的多重耐药细菌感染是促进该地区市场增长的一些因素。哮喘、慢性阻塞性肺病、肺炎和支气管炎等下呼吸道疾病给全球医疗保健系统带来了沉重负担。因此，这些疾病的日益流行将推动对下呼吸道疾病诊断和治疗的需求。据美国肺臟协会 (ALA) 称，约有 1000 万美国人因吸烟而患有急性支气管炎。因此，非营利性政府组织 (NGO) 与私人和政府机构合作，推出了各种活动和计划，以提高美国民众的认识。例如，2023 年 5 月，Grifols 在美国推出了首个免费的直接面向消费者的计划，以筛查 COPD 的遗传风险。该计划由一家生产血浆衍生药物和创新诊断技术的公司推出。该计划被命名为 AlphaID At Home。

市场参与者展望

服务于下呼吸道疾病诊断和治疗市场的主要公司包括：艾伯维公司、葛兰素史克公司、强生公司。有限公司、默克公司、诺华公司、武田製药有限公司等。市场参与者通过采取各种策略（包括併购、合作、合作、融资和新产品发布），为市场增长做出了巨大贡献，以保持市场竞争力。例如，2022 年 4 月，辉瑞公司和 ReViral Ltd. 签订了一项具有约束力的协议，根据协议，辉瑞以 5.25 亿美元的价格收购了 ReViral。通过此次收购，辉瑞旨在加强其传染病研发能力并增强其对呼吸道合胞病毒的治疗。

报告涵盖：

  • 2022年市场价值数据分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 全球下呼吸道疾病诊断和治疗市场的主要公司。根据现有数据，报告中还提供了与新产品发布相关的信息以及相关新闻。
  • 通过确定未来强劲增长的关键细分市场来分析业务战略。
  • 市场进入和市场扩张策略分析。
  • 通过识别市场中“谁的立场”来製定竞争策略。

目录

第 1 章：报告摘要

  • 当前行业分析及增长潜力展望
  • 研究方法和工具
  • 市场细分
    • 按细分
    • 按地区

第 2 章：市场概述和见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • F. Hoffmann-La Roche Ltd.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Pfizer Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Teva Pharmaceutical Industries Ltd.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 全球下呼吸道疾病分病诊治
    • 肺炎
    • 支气管炎
    • 结核病 (TB)
    • 其他（流感）
  • 全球下呼吸道疾病的诊断治疗
    • 粘液样本
    • 血液检查
    • 胸部 X 光检查
    • 脉搏血氧仪
  • 全球下呼吸道疾病的治疗诊断
    • 非甾体类抗炎药 (NSAID)
    • 镇痛解热药
    • 支气管扩张吸入器
    • 其他（抗生素）
  • 全球下呼吸道疾病分类诊断
    • 场外交易 (OTC)
    • 处方

第 5 章：区域分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca
  • Aurobindo Pharma
  • Bristol Myers Squibb's
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Private Limited
  • Lupin
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • SHIONOGI & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Ltd.
Product Code: OMR2027540

Title: Global Lower Respiratory Tract Disease Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Condition (Pneumonia, Bronchitis, Tuberculosis, and Others), by Diagnosis (Mucus Samples, Blood Tests, Chest X-Rays, and Pulse Oximetry), and by Treatment (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics and, Antipyretic Drugs, Bronchodilator Inhaler and Others), and by Category (Over-the-Counter (OTC) and Prescription),Forecast Period (2023-2030).

The global lower respiratory tract disease diagnosis and treatment market is anticipated to grow at a CAGR of 7.4% during the forecast period (2023-2030). The lower respiratory tract disease diagnosis and treatment market is driven by the rising incidence of lower respiratory tract diseases, the aging population, increased awareness and diagnosis, government initiatives and healthcare policies, environmental variables (such as air pollution, climate change, and allergens), and innovations in technology. Owing to the day-by-day degrading air quality of several nations around the globe has propelled the incidence of cold, cough, and allergies. Hence, there were several initiatives witnessed aiming to improve the air quality index (AQI) while providing well-efficient healthcare facilities for the treatment of such infections. For instance, in March 2023, the ultra-low emission zones (ULEZ) project in London employed mobile air quality monitoring technology to track air quality and intends to cut one million hospital admissions by 2050. It tries to prevent lower respiratory tract problems brought on by polluted air.

Segmental Outlook

The global lower respiratory tract disease diagnosis and treatment market is segmented by condition, diagnosis, treatment, and category. Based on the conditions, the market is sub-segmented into pneumonia, bronchitis, tuberculosis, and others (influenza). Based on the diagnosis, the market is sub-segmented into mucus samples, blood tests, chest X-rays, and pulse oximetry. Based on the treatment, the market is sub-segmented into NSAIDs, analgesics and antipyretics, bronchodilator inhalers, and others (antibiotics). Further, on the basis of category, the market is bifurcated into OTC and prescription. Among the conditions, the bronchitis sub-segment is anticipated to hold a considerable share of the market owing to the rise in prevalence of bronchitis cases coupled with the rise in development of new and more effective medications treating bronchitis.

The Bronchodilator Inhaler Sub-Segment is Anticipated to Hold a Considerable Share of the Market

Among the treatments, the bronchodilator inhaler sub-segment is expected to hold a considerable share of the global lower respiratory tract disease diagnosis and treatment market. The segmental growth is attributed to the growing influence of combination therapies. Combination therapies, which combine two or more bronchodilator inhaler medications, are becoming increasingly common as they provide better therapeutic results and are more convenient for patients. For instance, in August 2020, Teva Pharmaceutical Industries Ltd. introduced ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder, the first and only digital rescue inhaler approved for use in patients aged 4 years and above. The inhaler is used to treat and prevention bronchospasm in those with reversible obstructive airway disease, as well as for the avoidance of exercise-induced bronchospasm (EIB).

Regional Outlook

The global lower respiratory tract disease diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market across the globe, owing to the unhealthy lifestyles of the regional population. Expanding the healthcare infrastructure and increasing patient awareness are another factor to boost the regional market growth.

North America is Expected to Grow at a Significant CAGR in the Global Lower Respiratory Tract Disease Diagnosis and Treatment Market

Among all regions, the North America is anticipated to grow at a significant CAGR over the forecast period. Growing geriatric populations, immune-compromised seniors, and multi-drug resistant bacterial infections in children are some factors contributing to the region's market growth. Lower respiratory tract diseases, such as asthma, COPD, pneumonia, and bronchitis, among others, imposes a significant burden on global healthcare systems. Hence, the growing prevalence of these diseases will propel the demand for lower respiratory tract diseases diagnosis and treatments. According to the American Lung Association (ALA), around 10 million Americans are suffering from acute bronchitis, owing to the smoking. Resultantly, the non-profit government organization (NGOs) in collaboration with private and government institutions are introducing various campaigns and programmes creating awareness among the population in the US. For instance, in May 2023, Grifols, introduced first-ever free direct-to-consumer program in the US to screen for the genetic risk of COPD. The programme was unveiled by a company that produces plasma-derived medications and innovative diagnostic technologies. The initiative is named as AlphaID At Home.

Market Players Outlook

The major companies serving the lower respiratory tract disease diagnosis and treatment market include: AbbVie Inc., GlaxoSmithKline plc, Johnson & Johnson Pvt. Ltd., Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Pfizer Inc. and ReViral Ltd. entered into a binding agreement under which Pfizer acquired ReViral for worth $525 million. Through this acquisition, Pfizer aims to strengthen its infectious diseases R&D capabilities and enhance its treatment of RSVs.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global lower respiratory tract disease diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. F. Hoffmann-La Roche Ltd.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Pfizer Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Teva Pharmaceutical Industries Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Lower Respiratory Tract Disease Diagnosis and Treatment by Condition
    • 4.1.1. Pneumonia
    • 4.1.2. Bronchitis
    • 4.1.3. Tuberculosis (TB)
    • 4.1.4. Others (Influenza)
  • 4.2. Global Lower Respiratory Tract Disease Treatment by Diagnosis
    • 4.2.1. Mucus Samples
    • 4.2.2. Blood Tests
    • 4.2.3. Chest X-Rays
    • 4.2.4. Pulse Oximetry
  • 4.3. Global Lower Respiratory Tract Disease Diagnosis by Treatment
    • 4.3.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 4.3.2. Analgesics and Antipyretic Drugs
    • 4.3.3. Bronchodilator Inhalers
    • 4.3.4. Others (Antibiotics)
  • 4.4. Global Lower Respiratory Tract Disease Diagnosis by Category
    • 4.4.1. Over-the-Counter (OTC)
    • 4.4.2. Prescription

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott Laboratories
  • 6.2. AbbVie Inc.
  • 6.3. AstraZeneca
  • 6.4. Aurobindo Pharma
  • 6.5. Bristol Myers Squibb's
  • 6.6. GlaxoSmithKline plc
  • 6.7. Hikma Pharmaceuticals PLC
  • 6.8. Johnson & Johnson Private Limited
  • 6.9. Lupin
  • 6.10. Merck & Co., Inc.
  • 6.11. Novartis AG
  • 6.12. Sanofi
  • 6.13. SHIONOGI & Co., Ltd.
  • 6.14. Sun Pharmaceutical Industries Ltd.
  • 6.15. Takeda Pharmaceutical Company Ltd.

LIST OF TABLES

  • 1. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 2. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR PNEUMONIA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR BRONCHITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR TB MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR OTHER CONDITIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY MUCUS SAMPLES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY BLOOD TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY CHEST X-RAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY PULSE OXIMETRY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL LOWER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 12. GLOBAL NSAIDS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL ANALGESICS AND ANTIPYRETIC DRUGS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL BRONCHODILATOR INHALER FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL OTHER TREATMENTS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 17. GLOBAL OTC FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL PRESCRIPTION FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 25. EUROPEAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 27. EUROPEAN LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 28. EUROPEAN LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 29. EUROPEAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 33. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 34. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 39. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022 VS 2030 (%)
  • 2. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR PNEUMONIA MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR BRONCHITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR TB MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR OTHER CONDITIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022 VS 2030 (%)
  • 7. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY MUCUS SAMPLES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY BLOOD TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY CHEST X-RAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY PULSE OXIMETRY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022 VS 2030 (%)
  • 12. GLOBAL NSAIDS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL ANALGESICS AND ANTIPYRETIC DRUGS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL BRONCHODILATOR INHALER FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL OTHER TREATMENTS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 17. GLOBAL OTC FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL PRESCRIPTION FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. US LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)